Ignite Creation Date:
2025-12-25 @ 1:11 AM
Ignite Modification Date:
2026-02-24 @ 3:15 PM
Study NCT ID:
NCT03834493
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-18
First Post:
2019-02-06
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-07-28
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-05-29
Completion Date Type:
ESTIMATED
First Submit Date:
2019-02-06
First Submit QC Date:
None
Study First Post Date:
2019-02-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-11-27
Results First Submit QC Date:
None
Results First Post Date:
2023-12-20
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-08
Last Update Post Date:
2025-07-18
Last Update Post Date Type:
ACTUAL